Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment
- 31 August 2005
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (2) , S206-S213
- https://doi.org/10.1016/j.jaad.2005.04.064
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patientsJournal of Allergy and Clinical Immunology, 2003
- Atopic dermatitisThe Lancet, 2003
- Smallpox vaccination: Risk considerations for patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2002
- Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitisJournal of the American Academy of Dermatology, 2002
- Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitisJournal of Allergy and Clinical Immunology, 2001
- A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patientsJournal of the American Academy of Dermatology, 2001
- Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenJournal of the American Academy of Dermatology, 2001
- Atopic eczema is associated with delayed maturation of the antibody response to Pneumococcal vaccineClinical and Experimental Immunology, 2000
- Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic DermatitisArchives of Dermatology, 2000
- Natural History of Selective Antibody Deficiency to Bacterial Polysaccharide Antigens in ChildrenPediatric Asthma, Allergy & Immunology, 1998